drugset / Trial / NCT03924882
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and toxicity of anlotinib in patients with platinum resistant or refractory ovarian cancer
Timeline
- Start
- 2019-04-25
- Primary completion
- 2021-04-25
- Completion
- 2022-04-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |